Dilon Technologies is highlighting results from a clinical study presented at this week's American Society of Breast Surgeons (ASBS) meeting in San Diego indicating that the company's breast-specific gamma imaging (BSGI) technology can change patient management.
Researchers from Beth Israel Medical Center in New York City used a BSGI system to study 82 patients who were newly diagnosed with breast cancer. Researchers wanted to determine the number of patients with known breast cancer who were found to have an additional lesion detected by BSGI, but undetected by mammography.
In the study group, 22% of patients had a change in surgical management based on BSGI findings, and additional cancer was detected in 9% of patients. The researchers said that BSGI is an additional tool to detect breast cancers that otherwise might be missed by standard imaging, according to lead author Dr. Susan Boolbol.
Related Reading
Dilon touts gamma imaging research, March 18, 2009
Dilon Q4 sales increase, February 10, 2009
Dilon rolls out new collimators, February 3, 2009
Breast-specific gamma imaging reveals unseen cancers, December 4, 2008
Dilon partners with Terason, November 18, 2008
Copyright © 2009 AuntMinnie.com
